The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes

MLA

Mark Boldrin, et al. “The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes.” Diabetes Care, vol. 36, Feb. 2013, pp. 498–504. EBSCOhost, https://doi.org/10.2337/dc12-0709.

APA

Mark Boldrin, Robert E. Ratner, Julio Rosenstock, Geremia B. Bolli, Bogdan Balas, Bernard Charbonnel, & Raffaella Balena. (2013). The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes. Diabetes Care, 36, 498–504. https://doi.org/10.2337/dc12-0709

Chicago

Mark Boldrin, Robert E. Ratner, Julio Rosenstock, Geremia B. Bolli, Bogdan Balas, Bernard Charbonnel, and Raffaella Balena. 2013. “The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes.” Diabetes Care 36 (February): 498–504. doi:10.2337/dc12-0709.